socalTECH

FEBRUARY 25, 2009

William Taylor as vice president of marketing. Most recently, XIFIN said, Zaniboni was CFO of AviaraDx, while Taylor served as vice president of marketing and corporate development for Acclerys Inc. The company said it has hired Steve Zaniboni as chief financial officer and R.

Arcturus 100

Arcturus Marketing IBM IBM 100

socalTECH

MAY 16, 2014

TrueCar is trading on the NASDAQ Global Select Market as TRUE. TrueCar is venture backed by backed by USAA, Capricorn Investment Group, Upfront Ventures, Anthem Ventures, Vulcan Capital Growth Equity, Peppy Capital Partners, Arcturus Venture Capital, along with others. The company raised around $71.1M in the IPO offering.

Truecar 147

Truecar Pricing Arcturus Anthem 147

socalTECH

JANUARY 15, 2010

Monrovia-based Ondax , a manufacturer of holographic filters and semiconductor lasers for the industrial, defense, scientific and medical markets, announced this week that it has named Randy Heyler as its President and CEO. ONDAX is backed by Arcturus Capital, Prospector Equity Capital, and others.

Arcturus 124

Arcturus Chief Technology Officer Monrovia Equity 124

socalTECH

OCTOBER 24, 2008

Long Beach-based Digital Performance, which develops technology for online sales efforts in the after market automotive parts sector, is announcing Monday that it has raised $3.2M The round was led by Rincon Venture Partners, and also included Arcturus Capital and Momentum Venture Management. in a Series A funding round.

Arcturus 100

Arcturus Long Beach Resource Capital 100

socalTECH

OCTOBER 14, 2008

Lepler has served at Brandspeak in addition to providing marketing and other expertise to a large number of other firms; and Marcus joins from Faith Communications. The firm is backed by Anthem Venture Partners, Capital One Auto Finance, GRP Partners, Arcturus Capital, Callaway Cars and the Skoll Fund. READ MORE>>

Zag 100

Zag Arcturus GRP Partners Anthem 100

Xconomy

APRIL 17, 2020

The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn’t the only way for biotech companies to raise cash. Late last year Alnylam (NASDAQ: ALNY ) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol.

Equity 84

Equity Activity Marketing Company 84

Xconomy

MARCH 30, 2018

The strength of the IPO market is notable because the first quarter is typically the slowest time of the year for companies to go public, EY told Xconomy. The number of companies filing to go public in the U.S. Life science companies accounted for nearly one third of the quarter’s IPOs.

Activity 52

Activity Report Marketing Company 52